Keyphrases
H3 K27-altered
66%
Diffuse Midline Glioma
66%
Clinical Trials
41%
ClpP
40%
ONC201
37%
Mitochondrial Proteases
37%
Paxalisib
33%
Consensus Framework
33%
Antitumor Potential
33%
Therapeutic Targeting
33%
Older Adults
33%
Conductive Phase
33%
Current Therapeutics
33%
Pediatric Low-grade Glioma
33%
Preadolescent children
33%
Phase III Clinical Trial
33%
Diffuse Intrinsic Pontine Glioma
14%
High-grade Glioma
12%
Tumor
10%
Clinical Efficacy
10%
Glioma Patients
8%
Biomarkers of Response
8%
Mechanism of Action
8%
AKT1
7%
Metabolic Adaptation
7%
PI3K Signaling
7%
Functional Endpoints
6%
Interpretable Results
6%
Targeted Combination
6%
Clinical Trial Design
6%
Targeted Inhibitors
6%
Clinical Implementation
6%
Clinical Trial Phase II
6%
Clinical Trial Phases
6%
Novel Therapies
6%
Clinical Endpoints
6%
Therapy Development
6%
Targeted Therapeutics
6%
Treatment Duration
6%
Early Phase Clinical Trials
6%
Optimal Dosing Strategy
6%
Quality of Life
6%
Global Approach
6%
Predictive Biomarker
6%
Medicine and Dentistry
Ganglioglioma
100%
Clinical Trial
43%
Endopeptidase Clp
40%
Neoplasm
40%
Pediatrics
33%
Adolescence
33%
Pontine Glioma
26%
Protein Kinase B Inhibitor
13%
Biological Marker
12%
Akt Signaling
6%
Treatment Duration
6%
Protein Degradation
6%
Clinical Trial Design
6%
Targeted Therapeutic Agent
6%
Therapy Development
6%
Disease
6%
Quality of Life
6%
Respiratory Chain
6%
Childhood Cancer
6%
Homeostasis
6%
Pharmacodynamics
6%
Symptomatic Treatment
6%
Citric Acid Cycle
6%
Pi3K/Akt Signaling
6%
Pharmacokinetics
6%
